- Home
- SGMT vs TEAF Comparison
SGMT vs TEAF Comparison
Compare SGMT & TEAF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SGMT
- TEAF
- Stock Information
- Founded
- SGMT 2006
- TEAF 2017
- Country
- SGMT United States
- TEAF United States
- Employees
- SGMT N/A
- TEAF N/A
- Industry
- SGMT
- TEAF Trusts Except Educational Religious and Charitable
- Sector
- SGMT
- TEAF Finance
- Exchange
- SGMT Nasdaq
- TEAF Nasdaq
- Market Cap
- SGMT 159.0M
- TEAF 174.8M
- IPO Year
- SGMT 2023
- TEAF N/A
- Fundamental
- Price
- SGMT $4.39
- TEAF $12.33
- Analyst Decision
- SGMT Buy
- TEAF
- Analyst Count
- SGMT 6
- TEAF 0
- Target Price
- SGMT $23.00
- TEAF N/A
- AVG Volume (30 Days)
- SGMT 1.2M
- TEAF 56.1K
- Earning Date
- SGMT 11-13-2024
- TEAF 01-01-0001
- Dividend Yield
- SGMT N/A
- TEAF 9.20%
- EPS Growth
- SGMT N/A
- TEAF N/A
- EPS
- SGMT N/A
- TEAF N/A
- Revenue
- SGMT N/A
- TEAF N/A
- Revenue This Year
- SGMT N/A
- TEAF N/A
- Revenue Next Year
- SGMT N/A
- TEAF N/A
- P/E Ratio
- SGMT N/A
- TEAF N/A
- Revenue Growth
- SGMT N/A
- TEAF N/A
- 52 Week Low
- SGMT $2.39
- TEAF $11.11
- 52 Week High
- SGMT $20.71
- TEAF $13.30
- Technical
- Relative Strength Index (RSI)
- SGMT 44.30
- TEAF 57.73
- Support Level
- SGMT $4.06
- TEAF $11.84
- Resistance Level
- SGMT $7.38
- TEAF $12.21
- Average True Range (ATR)
- SGMT 0.63
- TEAF 0.14
- MACD
- SGMT -0.11
- TEAF 0.05
- Stochastic Oscillator
- SGMT 9.94
- TEAF 95.54
About SGMT Sagimet Biosciences Inc. Series A
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company focused on developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional lipid metabolism pathways. The company's lead drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of nonalcoholic steatohepatitis (NASH).
About TEAF Ecofin Sustainable and Social Impact Term Fund
Tortoise Essential Assets Income Term is a US-based non-diversified, closed-end management investment company. Its investment objective is to provide common shareholders with a high level of total return with an emphasis on current distributions.